Bloomberg News

Celgene May Bid for Human Genome, Reuters Says

July 08, 2012

(Corrects to say second bidder will propose merger of equals in second paragraph)

Celgene Corp. (CELG:US) is one of two companies other than GlaxoSmithKline Plc (GSK) weighing a bid for Human Genome Sciences Inc., Reuters says, citing a source familiar with the situation that it didn’t identify.

A second unidentified bidder would propose a merger of equals, Reuters said yesterday. Glaxo has offered to buy Human Genome for $13 a share, and the U.S. biotechnology company has set a July 16 deadline for competing bids.

To contact the reporter on this story: Makiko Kitamura in London at

To contact the editor responsible for this story: Dick Schumacher at

The Good Business Issue

Companies Mentioned

  • CELG
    (Celgene Corp)
    • $113.35 USD
    • 3.75
    • 3.31%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus